Novel Hydrocephalus Valve Addresses Postural Changes
|
By HospiMedica International staff writers Posted on 28 May 2020 |

Image: The M.blue adjustable gravitational valve with integrated fixed pressure differential valve (Photo courtesy of Aesculap)
New valve technology integrates gravitational technology with a fixed differential pressure unit into one valve, allowing for a simple, position-dependent hydrocephalus solution.
The Aesculap (Tuttlingen, Germany) M.blue valve is an adjustable gravitational valve with an integrated fixed pressure differential valve that together provide automatic adjustment of the opening pressure during the most active time of the day, when people are standing and moving about; the integration of the fixed pressure differential valve not only addresses the posture changes, and also counteracts the risk of possible over-drainage complications, especially in the upright and active body position.
The differential pressure unit is available in 0,5,10 and 15 cm H20, and is effective in all body positions. When lying down, the differential pressure unit acts alone. If the brain pressure rises above the selected opening pressure, a microspiral spring is activated to drain cerebrospinal fluid (CSF). The gravitational unit in the M.blue valve is adjustable from 0-40 cm H20 and is only activated in an upright body position. The combination of both units, gravitational and differential pressure unit, determines the total opening pressure of the M.blue valve.
Design feature include a durable, highly bio-compatible titanium shell, oxidized to display a shade of blue, and a soft touch mechanism that allows for comfortable adjustment. An active-lock mechanism protects it from unintentional reprogramming, not only after a magnetic resonance imaging (MRI) scan, but also from everyday magnets such as smartphones, tablets device, headphones, and hearing devices. For more challenging forms of hydrocephalus, the M.blue plus valve provides an adjustable differential pressure unit (the proGAV 2.0) to provide a customizable solution.
“The patient is our priority and we will continue to invest in research and development to create better solutions,” said Christoph Miethke, CEO and founder of MIETHKE (Potsdam, Germany), the manufacturer of the M.blue hydrocephalus valves for Aesculap. “Our focus on Hydrocephalus valves creates an expertise and openness to future developments that allows us to serve in a way that will improve the lives that we touch.”
“We are very pleased to be able to continue to provide healthcare teams with new and innovative solutions,” said Chuck DiNardo, President of Aesculap. “With our strong partnership with MIETHKE comes an impactful collaborative effort to bring better Hydrocephalus solutions to patients, such as the new M.blue valve.”
Hydrocephalus is a condition in which an excess of CSF accumulates within the ventricles and increases intracranial pressure (ICP) in the brain, resulting in a life-threatening situation. The challenge is to regulate CSF drainage to keep within normal physiological ranges. CSF tends to drain faster when a patient is standing, causing a decrease in ICP, which results in headaches, nausea and other debilitating symptoms. This necessitates the need for higher valve resistance in upright positions; the taller the patient, the higher the necessary resistance.
Related Links:
Aesculap
MIETHKE
The Aesculap (Tuttlingen, Germany) M.blue valve is an adjustable gravitational valve with an integrated fixed pressure differential valve that together provide automatic adjustment of the opening pressure during the most active time of the day, when people are standing and moving about; the integration of the fixed pressure differential valve not only addresses the posture changes, and also counteracts the risk of possible over-drainage complications, especially in the upright and active body position.
The differential pressure unit is available in 0,5,10 and 15 cm H20, and is effective in all body positions. When lying down, the differential pressure unit acts alone. If the brain pressure rises above the selected opening pressure, a microspiral spring is activated to drain cerebrospinal fluid (CSF). The gravitational unit in the M.blue valve is adjustable from 0-40 cm H20 and is only activated in an upright body position. The combination of both units, gravitational and differential pressure unit, determines the total opening pressure of the M.blue valve.
Design feature include a durable, highly bio-compatible titanium shell, oxidized to display a shade of blue, and a soft touch mechanism that allows for comfortable adjustment. An active-lock mechanism protects it from unintentional reprogramming, not only after a magnetic resonance imaging (MRI) scan, but also from everyday magnets such as smartphones, tablets device, headphones, and hearing devices. For more challenging forms of hydrocephalus, the M.blue plus valve provides an adjustable differential pressure unit (the proGAV 2.0) to provide a customizable solution.
“The patient is our priority and we will continue to invest in research and development to create better solutions,” said Christoph Miethke, CEO and founder of MIETHKE (Potsdam, Germany), the manufacturer of the M.blue hydrocephalus valves for Aesculap. “Our focus on Hydrocephalus valves creates an expertise and openness to future developments that allows us to serve in a way that will improve the lives that we touch.”
“We are very pleased to be able to continue to provide healthcare teams with new and innovative solutions,” said Chuck DiNardo, President of Aesculap. “With our strong partnership with MIETHKE comes an impactful collaborative effort to bring better Hydrocephalus solutions to patients, such as the new M.blue valve.”
Hydrocephalus is a condition in which an excess of CSF accumulates within the ventricles and increases intracranial pressure (ICP) in the brain, resulting in a life-threatening situation. The challenge is to regulate CSF drainage to keep within normal physiological ranges. CSF tends to drain faster when a patient is standing, causing a decrease in ICP, which results in headaches, nausea and other debilitating symptoms. This necessitates the need for higher valve resistance in upright positions; the taller the patient, the higher the necessary resistance.
Related Links:
Aesculap
MIETHKE
Latest Surgical Techniques News
- Ultrasound Technology Aims to Replace Invasive BPH Procedures
- Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
- New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
- Robot-Assisted Brain Angiography Improves Procedural Outcomes
- Brain Mapping Technology Enhances Precision in Brain Tumor Resection
- Handheld Robotic System Expands Options for Total Knee Surgery
- VR Experience Reduces Patient Anxiety Before Kidney Stone Procedure
- Injectable Mini Livers Offer Hope for Patients Awaiting Transplant
- Pulsed Field Ablation Technology Cleared in Europe for Persistent AFib
- AI-Powered Imaging Brings Real-Time Margin Clarity to Breast Cancer Surgery
- Minimally Invasive Device Safely Treats Challenging Brain Aneurysms
- Surgical Robot Makes Complex Liver Tumor Surgery Safer and Less Invasive
- Neurostimulation Implant Reduces Seizure Burden in Drug-Resistant Epilepsy
- Minimally Invasive Procedure Effectively Treats Small Kidney Cancers
- Fluorescence Probe Paired with Engineered Enzymes Lights Up Tumors for Easier Surgical Removal
- Novel Hydrogel Could Become Bone Implant of the Future
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read more
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







